CFC assays provide more predictive indications of the clinical situation than data derived using cell lines. Therefore, they are of particular utility when the goal is to identify toxic compounds and exclude them before costly clinical trials commence. Previous estimates indicate that the average drug takes 10-15 years to get to market at a cost of approximately $800 million, however more recent indications are that costs are even higher*. The use of exquisitely sensitive tests such as CFC assays within the drug screening process can help to eliminate late drug failure, and avoid costs associated with further development. However, despite the obvious value and utility of CFC assays in the drug development process, they are perceived by many to be time-consuming and technically challenging. ReachBio removes these obstacles and makes the power of sensitive CFC assays available to biopharma organizations of all sizes by providing fee-for-service access to highly trained and knowledgeable scientists with many years experience in performing reproducible CFC assays and interpreting the resulting data.
* DiMasi, J. A. and Grabowski, H. G. (2007), The cost of biopharmaceutical R&D: is biotech different?. Manage. Decis. Econ., 28: 469–479. doi: 10.1002/mde.1360
The traditional drug-development process. ReachBio provides services for clients involved in preclinical through clinical drug development. Adapted from Pharmaceutical Industry Profile 206, PhRMA, March 2006.